NYSE:MRK - Merck & Co., Inc. Stock Price, Price Target & More

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc. declared a quarterly dividend on Tuesday, May 22nd. Stockholders of record on Friday, June 15th will be given a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 annualized dividend and a dividend yield of 3.05%. The ex-dividend date is Thursday, June 14th. View Merck & Co., Inc.'s Dividend History.

Merck & Co., Inc. announced that its board has authorized a stock buyback plan on Saturday, December 2nd 2017, which allows the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings results on Tuesday, May, 1st. The company reported $1.05 earnings per share for the quarter, topping analysts' consensus estimates of $1.00 by $0.05. The business had revenue of $10.04 billion for the quarter, compared to analysts' expectations of $10.09 billion. Merck & Co., Inc. had a return on equity of 30.93% and a net margin of 4.31%. Merck & Co., Inc.'s revenue was up 6.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 EPS. View Merck & Co., Inc.'s Earnings History.

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co., Inc..

Merck & Co., Inc. updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion.

18 brokers have issued twelve-month price objectives for Merck & Co., Inc.'s stock. Their forecasts range from $58.83 to $72.00. On average, they expect Merck & Co., Inc.'s share price to reach $66.0519 in the next twelve months. This suggests a possible upside of 5.0% from the stock's current price. View Analyst Ratings for Merck & Co., Inc..

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Merck & Co., Inc. saw a decrease in short interest in June. As of June 29th, there was short interest totalling 17,153,866 shares, a decrease of 21.6% from the June 15th total of 21,867,505 shares. Based on an average trading volume of 11,109,077 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.6% of the shares of the stock are sold short. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Press coverage about MRK stock has trended somewhat positive recently, according to Accern. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merck & Co., Inc. earned a coverage optimism score of 0.12 on Accern's scale. They also assigned media headlines about the company an impact score of 46.06 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Merck & Co., Inc.'s stock is owned by many different of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.29%), Swedbank (0.15%), NN Investment Partners Holdings N.V. (0.08%), Manning & Napier Group LLC (0.07%), Gateway Investment Advisers LLC (0.05%) and Hexavest Inc. (0.05%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Hexavest Inc., Manning & Napier Group LLC, Radnor Capital Management LLC, Clinton Group Inc., Fulton Bank N.A., Fjarde AP Fonden Fourth Swedish National Pension Fund, Swedbank and Lodestar Investment Counsel LLC IL. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

MRK stock was purchased by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, LGT Capital Partners LTD., DnB Asset Management AS, Handelsbanken Fonder AB, Gofen & Glossberg LLC IL, Fisher Asset Management LLC, Neville Rodie & Shaw Inc. and Chesley Taft & Associates LLC. View Insider Buying and Selling for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $62.89.

Merck & Co., Inc. has a market capitalization of $169.56 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co., Inc. employs 69,000 workers across the globe.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]